GO:0003938 IMP dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003938 IMP dehydrogenase activity catalyzes the NAD+-dependent oxidation of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP), the rate-limiting step in de novo guanine nucleotide biosynthesis.
• The reaction is formally: IMP + NAD+ + H2O = XMP + NADH + H+, and it is the committed step for guanylate pool expansion.
• IMPDH enzymes are established drug targets; inhibitors such as tiazofurin and mycophenolic acid suppress activity and modulate guanylate metabolism in cancer and immune cells [2,3,8].
• IMPDH activity is required for viral RNA replication, including norovirus, making it a host-directed antiviral target.
• Pathogen IMPDHs, such as Helicobacter pylori and Cryptosporidium IMPDH, are structurally distinct and are pursued as selective anti-infective targets [5,7].
• IMPDH2 activation supports stemness in castration-resistant prostate cancer, linking this enzymatic activity to tumor progression.
Description
IMP dehydrogenase activity (GO:0003938) is a molecular function that catalyzes the NAD+-dependent conversion of inosine 5'-monophosphate (IMP) to xanthosine 5'-monophosphate (XMP). This reaction is the rate-limiting and committed step in de novo guanine nucleotide biosynthesis, controlling the size of the guanylate pool available for RNA, DNA, and GTP-dependent signaling. Because guanine nucleotides are required for nucleic acid synthesis, protein glycosylation, and signal transduction, IMP dehydrogenase activity sits at a metabolic hub that influences cell proliferation, differentiation, and immune responses. The enzyme is also a validated pharmacological target: inhibitors such as tiazofurin and mycophenolic acid reduce IMP dehydrogenase activity and alter guanylate metabolism in tumor and immune cells [2,3,8]. In oncology, increased IMP dehydrogenase activity, amount, and altered kinetic properties have been documented in mycophenolic acid-resistant neuroblastoma cells, indicating that this activity can be selected for under drug pressure. In infectious disease, IMP dehydrogenase activity is required for norovirus replication, and pathogen-specific IMPDH enzymes from Helicobacter pylori and Cryptosporidium have been structurally characterized as anti-infective targets [4,5,7]. Recent work shows that IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation, directly connecting this enzymatic activity to a clinically aggressive disease state. For researchers, GO:0003938 therefore represents both a core metabolic function and a tractable node for therapeutic intervention, biomarker discovery, and mechanistic studies of nucleotide metabolism [1,2,4].
IMP dehydrogenase activity At A Glance
| GO ID | GO:0003938 |
|---|---|
| GO term | IMP dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | IMP:NAD+ oxidoreductase activity; IMP oxidoreductase activity; inosinate dehydrogenase activity; inosine 5'-monophosphate dehydrogenase activity; inosine-5'-phosphate dehydrogenase activity; inosine monophosphate dehydrogenase activity; inosine monophosphate oxidoreductase activity; inosinic acid dehydrogenase activity |
| Major function | Catalyzes the NAD+-dependent oxidation of IMP to XMP, the rate-limiting step in de novo guanine nucleotide biosynthesis |
| Reaction | IMP + NAD+ + H2O = XMP + NADH + H+ |
| Pathway context | De novo guanine nucleotide biosynthesis; guanylate pool maintenance |
| Representative enzymes | IMPDH1, IMPDH2 (human); pathogen IMPDHs from Helicobacter pylori and Cryptosporidium [1,5,7] |
| Pharmacological relevance | Target of tiazofurin, mycophenolic acid, and other IMPDH inhibitors [2,3,6,8] |
What Is GO:0003938?
GO:0003938 IMP dehydrogenase activity is defined as the catalysis of the reaction: inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+. In this reaction, the substrate IMP is oxidized at the C2 position of the purine ring to form XMP, while NAD+ is reduced to NADH and a proton is released. This activity is synonymous with IMP:NAD+ oxidoreductase activity, IMP oxidoreductase activity, inosinate dehydrogenase activity, inosine 5'-monophosphate dehydrogenase activity, inosine-5'-phosphate dehydrogenase activity, inosine monophosphate dehydrogenase activity, inosine monophosphate oxidoreductase activity, and inosinic acid dehydrogenase activity. The reaction is the first committed and rate-limiting step in de novo guanine nucleotide biosynthesis, making GO:0003938 a central control point for guanylate pool homeostasis.
Why Is IMP dehydrogenase activity Important in Cell Biology?
IMP dehydrogenase activity (GO:0003938) is important because it controls the committed step of de novo guanine nucleotide biosynthesis, thereby regulating the supply of GTP and dGTP for nucleic acid synthesis, GTP-dependent signaling, and glycosylation reactions. Because proliferating cells and activated immune cells have high guanylate demands, this activity is a determinant of cell growth and immune function, and its inhibition produces immunomodulatory effects. In cancer, elevated or altered IMP dehydrogenase activity has been linked to drug resistance and to stemness maintenance in castration-resistant prostate cancer [1,6]. In infectious disease, IMP dehydrogenase activity is required for norovirus replication, and pathogen-specific IMPDH enzymes are targets for antibacterial and antiparasitic drug development [4,5,7]. Consequently, GO:0003938 is relevant to oncology, immunology, virology, and antimicrobial discovery, and it is a frequent focus of mechanistic and pharmacological studies [1,2,4,5,7].
• Rate-limiting step in de novo guanine nucleotide biosynthesis, controlling guanylate pool size.
• Required for RNA and DNA synthesis because it supplies XMP for GMP, GDP, and GTP production.
• Validated target of immunomodulatory and anticancer inhibitors such as tiazofurin and mycophenolic acid [2,3,8].
• Increased activity and altered kinetics are associated with mycophenolic acid resistance in neuroblastoma cells.
• Supports norovirus replication, making it a host-directed antiviral target.
• Pathogen IMPDHs from Helicobacter pylori and Cryptosporidium are structurally distinct anti-infective targets [5,7].
• IMPDH2 activation downstream of IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer.
• Modulation of IMP dehydrogenase activity alters guanylate metabolism in cells.
• Provides a metabolic checkpoint linking nucleotide metabolism to cell proliferation and differentiation [1,2].
• Enables selective targeting because pathogen and human IMPDH enzymes differ structurally [5,7].
Molecular Mechanism of IMP dehydrogenase activity
Substrate recognition and binding of IMP
In simple terms: The enzyme first grabs its starting material, IMP, and holds it in place.
IMP dehydrogenase activity (GO:0003938) begins with binding of the substrate inosine 5'-monophosphate (IMP) in the active site, positioning the purine ring for oxidation at the C2 position. Structural studies of Cryptosporidium IMP dehydrogenase bound to an inhibitor show a well-defined substrate pocket that accommodates the IMP moiety and coordinates catalytic residues. Because IMP is the branch-point metabolite between adenine and guanine nucleotide pathways, its recognition by IMPDH commits the cell to guanylate synthesis.
NAD+-dependent hydride transfer and formation of XMP
In simple terms: The enzyme uses NAD+ as an oxidizing agent to convert IMP into XMP.
The catalytic mechanism of GO:0003938 involves NAD+-dependent oxidation of IMP to xanthosine 5'-monophosphate (XMP), with concomitant reduction of NAD+ to NADH and release of a proton: IMP + NAD+ + H2O = XMP + NADH + H+. This hydride transfer step is the chemical core of the activity and is the point at which guanylate biosynthesis becomes committed. Inhibitors such as tiazofurin and mycophenolic acid interfere with this catalytic cycle, reducing XMP formation and depleting guanylate pools [2,3,8].
Cofactor requirements and metal independence
In simple terms: The enzyme needs NAD+ as a cofactor but does not require metal ions for the reaction.
GO:0003938 requires NAD+ as the electron acceptor and water as a reactant, producing NADH and H+ in addition to XMP. The reaction is NAD+-dependent and does not require a metal cofactor, distinguishing it from some other oxidoreductases. Structural analyses of IMP dehydrogenase-inhibitor complexes confirm that the NAD+ binding site and the IMP binding site are adjacent, allowing efficient hydride transfer.
Oligomeric assembly and kinetic regulation
In simple terms: The enzyme can change its shape and assembly state to tune how fast it works.
IMP dehydrogenase enzymes can exist in different oligomeric states, and this assembly behavior influences catalytic activity and regulation. In mycophenolic acid-resistant neuroblastoma cells, IMP dehydrogenase showed increased activity, increased amount, and altered kinetic properties, indicating that changes in enzyme level and kinetics can modulate flux through GO:0003938. Modulation of IMP dehydrogenase activity by tiazofurin also alters guanylate metabolism, demonstrating that the reaction rate is responsive to pharmacological perturbation.
Inhibition by pharmacological agents
In simple terms: Drugs can block this enzyme, which lowers guanine nucleotide levels.
GO:0003938 is inhibited by compounds such as tiazofurin and mycophenolic acid, which reduce XMP production and deplete guanylate pools [2,3,6,8]. Inhibition by tiazofurin of IMP dehydrogenase activity has been demonstrated in extracts of ovarian carcinomas, supporting the enzyme as an anticancer target. IMP dehydrogenase inhibitors also act as immunomodulators, reflecting the dependence of immune cell function on guanylate synthesis. In antiviral research, inhibition of IMP dehydrogenase exerts moderate to potent antiviral activity against norovirus replication.
Key Genes Involved in GO:0003938 IMP dehydrogenase activity
The genes and proteins below are directly associated with IMP dehydrogenase activity (GO:0003938) or with its regulation, pharmacology, and disease relevance as documented in the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IMPDH1 | Human IMP dehydrogenase isoform catalyzing IMP to XMP conversion | Target of inhibitors; studied for retinal and immune-related effects [2,3] |
| IMPDH2 | Human IMP dehydrogenase isoform; activated downstream of IMPA1-derived inositol | Supports stemness in castration-resistant prostate cancer |
| IMPA1 | Produces inositol that activates IMPDH2 | Links inositol metabolism to IMP dehydrogenase activity in prostate cancer |
| HpIMPDH | Helicobacter pylori IMP dehydrogenase | Antibacterial target; inhibitor design and evaluation |
| CpIMPDH | Cryptosporidium IMP dehydrogenase | Antiparasitic target; structure with inhibitor showing in vivo activity |
| Norovirus RdRp | Viral RNA-dependent RNA polymerase requiring guanylate pools | IMP dehydrogenase inhibition reduces norovirus replication |
| Tiazofurin target | Pharmacological inhibitor of IMP dehydrogenase | Modulates guanylate metabolism and ovarian carcinoma extracts [3,8] |
| Mycophenolic acid target | Pharmacological inhibitor of IMP dehydrogenase | Selects for resistant neuroblastoma cells with altered enzyme |
| Guanylate kinase | Downstream enzyme using GMP for GDP/GTP synthesis | Context for guanylate pool flux |
| GMP synthase | Converts XMP to GMP downstream of IMP dehydrogenase | Downstream of GO:0003938 in guanine nucleotide biosynthesis |
| PRPP synthetase | Provides PRPP for purine biosynthesis upstream of IMP | Upstream metabolic context |
| Adenylosuccinate lyase | Purine biosynthesis enzyme at the IMP branch point | Context for IMP partitioning |
| Nucleoside diphosphate kinase | Balances nucleotide pools including guanylates | Context for GTP homeostasis |
| Rho GTPases | GTP-binding signaling proteins dependent on guanylate pools | Downstream signaling affected by IMP dehydrogenase activity |
| Ras GTPases | GTP-binding signaling proteins dependent on guanylate pools | Downstream signaling affected by IMP dehydrogenase activity |
| mTOR pathway components | Growth signaling that can influence nucleotide demand | Context for proliferation-linked guanylate synthesis |
| c-Myc | Proliferation-associated transcription factor | Context for increased nucleotide demand in cancer |
How Is IMP dehydrogenase activity Regulated?
IMP dehydrogenase activity (GO:0003938) is regulated at multiple levels, including enzyme abundance, kinetic properties, and allosteric/oligomeric state. In mycophenolic acid-resistant neuroblastoma cells, increased activity and amount of IMP dehydrogenase with altered kinetic properties demonstrate that selection pressure can upregulate this activity. Pharmacological modulation by tiazofurin changes IMP dehydrogenase activity and guanylate metabolism, showing that flux through the reaction is responsive to inhibitor exposure. In castration-resistant prostate cancer, IMPA1-derived inositol maintains stemness via IMPDH2 activation, indicating that upstream metabolic signals can regulate IMP dehydrogenase activity. Inhibitors such as mycophenolic acid and tiazofurin act as immunomodulators by suppressing this activity, further illustrating its regulatory role in immune cell function.
IMP dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IMPDH2 | Castration-resistant prostate cancer stemness | IMPDH2 knockout or point-mutation in prostate cancer cell lines |
| IMPDH1/IMPDH2 | Drug resistance in neuroblastoma | Mycophenolic acid-resistant neuroblastoma cells with IMPDH overexpression |
| IMPDH1/IMPDH2 | Ovarian carcinoma proliferation | Tiazofurin-treated ovarian carcinoma extracts and cell lines |
| HpIMPDH | Helicobacter pylori infection | HpIMPDH inhibitor evaluation in bacterial cultures |
| CpIMPDH | Cryptosporidiosis | Cryptosporidium IMPDH inhibitor studies with in vivo activity |
Cancer and drug resistance
IMP dehydrogenase activity (GO:0003938) is linked to cancer through its role in supplying guanine nucleotides for proliferation. In castration-resistant prostate cancer, IMPA1-derived inositol maintains stemness via IMPDH2 activation, directly connecting this activity to a lethal disease state. Increased activity, amount, and altered kinetic properties of IMP dehydrogenase were observed in mycophenolic acid-resistant neuroblastoma cells, suggesting that upregulation of this activity can contribute to drug resistance. Inhibition of IMP dehydrogenase by tiazofurin reduces activity in ovarian carcinoma extracts, supporting the enzyme as a therapeutic target in gynecologic cancers.
Immune modulation and transplantation
Because guanine nucleotide biosynthesis is required for lymphocyte proliferation, IMP dehydrogenase inhibitors act as immunomodulators. Mycophenolic acid, a well-known IMP dehydrogenase inhibitor, suppresses this activity and is used to modulate immune responses. This makes GO:0003938 a relevant target for understanding immunosuppressive mechanisms and for designing immunomodulatory agents.
Viral and parasitic infections
IMP dehydrogenase activity is required for norovirus replication, and inhibition of this activity exerts moderate to potent antiviral effects. Pathogen-specific IMPDH enzymes from Helicobacter pylori and Cryptosporidium are structurally distinct from human IMPDH and are pursued as selective anti-infective targets [5,7]. The Cryptosporidium IMPDH structure bound to an inhibitor with in vivo antiparasitic activity provides a template for drug design against GO:0003938 in parasites.
From IMP dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IMPDH2 reduce guanylate pools and proliferation? | IMPDH2 knockout cell line |
| Does a catalytic-site mutation abolish IMP dehydrogenase activity? | Point-mutation knock-in of IMPDH2 catalytic residue |
| Does tagging IMPDH2 affect localization and complex formation? | Tagged knock-in of IMPDH2 |
| Does IMPDH2 overexpression drive stemness or drug resistance? | IMPDH2 overexpression cell model [1,6] |
| Can pathogen IMPDH inhibitors selectively block HpIMPDH? | HpIMPDH inhibitor assays in bacterial systems |
| Does IMP dehydrogenase inhibition reduce norovirus replication? | Norovirus replication model with IMPDH inhibitors |
How to Study the IMP dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | IMP dehydrogenase catalytic activity | Inhibitor screening and kinetic studies |
| HPLC metabolite profiling | IMP, XMP, GMP, GDP, GTP levels | Guanylate pool analysis after perturbation [1,8] |
| X-ray crystallography | Three-dimensional structure of IMPDH-inhibitor complexes | Structure-guided inhibitor design [5,7] |
| Antiviral replication assay | Norovirus replication efficiency | Testing IMPDH inhibitors as antivirals |
| Enzyme kinetics | Km, Vmax, and altered kinetic properties | Characterizing resistant or mutant enzymes |
| Cell proliferation assay | Growth dependence on guanylate synthesis | Evaluating IMPDH knockout or inhibition |
| Western blot | IMPDH protein amount | Correlating activity with enzyme level |
| In vivo antiparasitic model | Parasite burden reduction | Testing CpIMPDH inhibitors |
Enzymatic activity assays
IMP dehydrogenase activity (GO:0003938) can be measured spectrophotometrically by monitoring NADH production at 340 nm or XMP formation, as demonstrated in ovarian carcinoma extracts treated with tiazofurin. Such assays are used to quantify inhibitor potency and to compare enzyme kinetics between wild-type and mutant enzymes [3,6].
Metabolite profiling and guanylate pool analysis
Because GO:0003938 controls guanylate pool size, metabolite profiling by HPLC or mass spectrometry can measure IMP, XMP, GMP, GDP, and GTP levels after genetic or pharmacological perturbation [1,8]. Modulation of IMP dehydrogenase activity by tiazofurin alters guanylate metabolism, which can be tracked by such methods.
Structural biology and inhibitor binding
X-ray crystallography of IMP dehydrogenase bound to inhibitors, as shown for Cryptosporidium IMPDH, reveals the architecture of the IMP and NAD+ binding sites and guides selective inhibitor design. Structural studies of HpIMPDH similarly support the development of pathogen-specific inhibitors.
Antiviral and antimicrobial efficacy testing
Inhibition of IMP dehydrogenase activity can be tested for antiviral effects against norovirus replication, where moderate to potent activity has been observed. For bacterial and parasitic targets, inhibitor evaluation against HpIMPDH and CpIMPDH provides proof of concept for anti-infective development [5,7].
How CRISPR Can Be Used to Study GO:0003938 IMP dehydrogenase activity
Knockout
CRISPR knockout of IMPDH1 or IMPDH2 can eliminate IMP dehydrogenase activity (GO:0003938) and reveal its requirement for guanylate pool maintenance and cell proliferation. Such models are useful for testing whether cancer cell stemness or drug resistance depends on IMPDH2 [1,6].
Point Mutation
Point-mutation knock-in of catalytic residues in IMPDH can dissect the hydride transfer step of GO:0003938 and separate catalytic activity from scaffolding functions. Point mutations can also model resistance-associated kinetic changes observed in mycophenolic acid-resistant cells.
Knock-in
Tagged knock-in of IMPDH allows tracking of enzyme localization, assembly, and interaction partners in live cells, providing insight into how GO:0003938 is regulated in context. Knock-in of pathogen IMPDH variants can support inhibitor selectivity studies [5,7].
Overexpression
CRISPR-mediated overexpression of IMPDH2 can test whether increased IMP dehydrogenase activity drives stemness, proliferation, or drug resistance, as suggested by IMPA1-IMPDH2 signaling in prostate cancer. Overexpression models also help validate inhibitor specificity.
How EDITGENE Supports IMP dehydrogenase activity Research
Researchers studying IMP dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in guanylate metabolism, cell proliferation, or drug response. EDITGENE provides publication-ready CRISPR cell models and screening services that enable precise interrogation of GO:0003938 and its regulatory network.
Contact EDITGENE today to design your custom CRISPR model for IMP dehydrogenase activity research.
Frequently Asked Questions About IMP dehydrogenase activity
What is IMP dehydrogenase activity?
IMP dehydrogenase activity (GO:0003938) is the catalysis of the reaction IMP + NAD+ + H2O = XMP + NADH + H+, the rate-limiting step in de novo guanine nucleotide biosynthesis.
What genes are involved in IMP dehydrogenase activity?
Key genes include IMPDH1 and IMPDH2 in humans, as well as pathogen IMPDH genes from Helicobacter pylori and Cryptosporidium [1,5,7].
What is the reaction catalyzed by GO:0003938?
The reaction is inosine 5'-phosphate + NAD+ + H2O = xanthosine 5'-phosphate + NADH + H+.
Why is IMP dehydrogenase activity important in cancer?
It supplies guanine nucleotides for proliferation, and IMPDH2 activation supports stemness in castration-resistant prostate cancer.
What drugs inhibit IMP dehydrogenase activity?
Tiazofurin and mycophenolic acid are well-known inhibitors that reduce IMP dehydrogenase activity and guanylate metabolism [2,3,6,8].
Is IMP dehydrogenase activity a antiviral target?
Yes, inhibition of IMP dehydrogenase exerts moderate to potent antiviral activity against norovirus replication.
How is IMP dehydrogenase activity measured?
It can be measured by NADH production or XMP formation in enzymatic assays, and by metabolite profiling of guanylate pools [3,8].
What is the role of IMPDH2 in prostate cancer?
IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.
Are pathogen IMPDH enzymes different from human IMPDH?
Yes, Helicobacter pylori and Cryptosporidium IMPDH enzymes are structurally distinct and are pursued as selective anti-infective targets [5,7].
How can CRISPR help study IMP dehydrogenase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of IMPDH genes in guanylate metabolism and disease [1,6].
Conclusion
IMP dehydrogenase activity (GO:0003938) is a central metabolic function that catalyzes the committed step of de novo guanine nucleotide biosynthesis and controls guanylate pool homeostasis. Its importance spans cancer, immune modulation, and infectious disease, with validated inhibitors and pathogen-specific enzymes providing therapeutic opportunities [1,2,4,5,7]. CRISPR-based models and pharmacological tools now allow precise interrogation of this activity in health and disease [1,6].
References
- 1. Hsu CC et al.. 2024. IMPA1-derived inositol maintains stemness in castration-resistant prostate cancer via IMPDH2 activation.. J Exp Med 221(11) PMID: 39470689
- 2. Mitchell BS et al.. 1993. IMP dehydrogenase inhibitors as immunomodulators.. Ann N Y Acad Sci 685:217-24 PMID: 8103312
- 3. Look KY et al.. 1992. Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas.. Gynecol Oncol 47(1):66-70 PMID: 1358769
- 4. Dang W et al.. 2017. Inhibition of Calcineurin or IMP Dehydrogenase Exerts Moderate to Potent Antiviral Activity against Norovirus Replication.. Antimicrob Agents Chemother 61(11) PMID: 28807916
- 5. Sahu NU et al.. 2019. Design, synthesis, and biological evaluation of Helicobacter pylori inosine 5'-monophosphate dehydrogenase (HpIMPDH) inhibitors.. Drug Dev Res 80(1):125-132 PMID: 30381846
- 6. Hodges SD et al.. 1989. Increased activity, amount, and altered kinetic properties of IMP dehydrogenase from mycophenolic acid-resistant neuroblastoma cells.. J Biol Chem 264(30):18137-41 PMID: 2572589
- 7. Kim Y et al.. 2015. Structure of Cryptosporidium IMP dehydrogenase bound to an inhibitor with in vivo antiparasitic activity.. Acta Crystallogr F Struct Biol Commun 71(Pt 5):531-8 PMID: 25945705
- 8. Lui MS et al.. 1984. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).. J Biol Chem 259(8):5078-82 PMID: 6143752
